Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.31 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.31 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13028968 | 0.95 | MEN1 (0.50) | TSHRMAPK1MEN1KMT2AALDH1A1 | |
| SCHEMBL9286584 | 0.91 | TSHR (0.46) | TSHRMAPK1MEN1KMT2AALDH1A1 | |
| SCHEMBL1219820 | 0.91 | MEN1 (0.50) | TSHRMAPK1MEN1KMT2AALDH1A1 | |
| SCHEMBL21855420 | 0.91 | MEN1 (0.50) | TSHRMAPK1MEN1KMT2AALDH1A1 | |
| SCHEMBL28098697 | 0.91 | MEN1 (0.50) | TSHRMAPK1MEN1KMT2AALDH1A1 | |
| SCHEMBL9418830 | 0.90 | TSHR (0.36) | TSHRMAPK1MEN1KMT2AALDH1A1 | |
| SCHEMBL1357542 | 0.90 | TSHR (0.47) | TSHRMAPK1MEN1KMT2AALDH1A1 | |
| SCHEMBL9559516 | 0.89 | TSHR (0.38) | TSHRMAPK1MEN1KMT2AALDH1A1 | |
| SCHEMBL5502602 | 0.87 | TSHR (0.45) | TSHRMAPK1MEN1KMT2AALDH1A1 | |
| SCHEMBL14644928 | 0.87 | TSHR (0.45) | TSHRMAPK1MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304604-A1 | ORGANOSILANES FOR THE TREATMENT OF INFECTIONS | TOPIKOS SCIENTIFIC, INC. (US) | 2025-10-02 | — | — | US | disclosed |
| US-12180239-B2 | Organosilanes for the treatment of infections | TOPIKOS SCIENTIFIC, INC. (US) | 2024-12-31 | — | — | US | disclosed |
| US-20230295195-A1 | ANTIMICROBIAL ORGANOSILANES | Tipikos Pharmaceuticals, Inc. (US) | 2023-09-21 | — | — | US | disclosed |
| EP-3298119-B2 | SURFACTANT AND DETERGENT COMPOSITIONS CONTAINING ETHOXYLATED GLYCERINE | PROCTER & GAMBLE (US) | 2022-05-25 | — | — | EP | disclosed |
| US-20210253607-A1 | ORGANOSILANES FOR THE TREATMENT OF INFECTIONS | TOPIKOS PHARMACEUTICALS, INC. (US) | 2021-08-19 | — | — | US | disclosed |
| US-20200248102-A1 | METHOD OF MAKING SURFACTANT COMPOSITIONS AND DETERGENT COMPOSITIONS | PROCTER & GAMBLE (US) | 2020-08-06 | — | — | US | disclosed |
| US-10640733-B2 | Surfactant and detergent compositions containing ethoxylated glycerine | The Procter & Gamble Company LLC (US) | 2020-05-05 | — | — | US | disclosed |
| US-10640734-B2 | Surfactant and detergent compositions containing ethoxylated glycerine | THE PROCTER & GAMBLE COMPANY (US) | 2020-05-05 | — | — | US | disclosed |
| WO-2020082026-A1 | ORGANOSILANES FOR THE TREATMENT OF INFECTIONS | TOPIKOS PHARMACEUTICALS, INC. (US) | 2020-04-23 | — | — | WO | disclosed |
| EP-3298119-B1 | SURFACTANT AND DETERGENT COMPOSITIONS CONTAINING ETHOXYLATED GLYCERINE | PROCTER & GAMBLE (US) | 2019-04-24 | — | — | EP | disclosed |
| US-20100286101-A1 | PHARMACEUTICAL COMPOSITION INCLUDING A CORTICOSTEROID AND A VITAMIN D ANALOG HAVING IMPROVED STABILITY | CARBOL JASON | 2010-11-11 | — | — | US | disclosed |
| CN-101810544-A | Method of making up and the device of realizing this method are made up in the using base layer photoactivation | OREAL | 2010-08-25 | — | — | CN | disclosed |
| CN-101810545-A | The method and the photosensitization composition for cosmetics of making up made up in photoactivation | OLIER PARIS CO LTD | 2010-08-25 | — | — | CN | disclosed |
| EP-1172400-B1 | THERMOPLASTIC RESIN FILM WITH SATISFACTORY PRINTABILITY | YUPO CORP (JP) | 2005-12-28 | — | — | EP | disclosed |
| US-6586106-B2 | Ink transfer, adhesion and aging stability, and being satisfactory in back ghost when offset printing using oxidation polymerization type ink is performed on both faces | YUPO CORPORATION (JP) | 2003-07-01 | — | — | US | disclosed |
| US-20020054991-A1 | Thermoplastic resin film satisfactory in printability | YUPO CORPORATION (JP) | 2002-05-09 | — | — | US | disclosed |
| EP-1172400-A1 | THERMOPLASTIC RESIN FILM WITH SATISFACTORY PRINTABILITY | Yupo Corporation (JP) | 2002-01-16 | — | — | EP | disclosed |
| US-5880130-A | TREATMENT OF CELL-PROLIFERATION DISEASES | ZENECA LIMITED (GB) | 1999-03-09 | — | — | US | disclosed |
| EP-0733045-A1 | 4,6-DIANILINO-PYRIMIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS TYROSINE KINASE INHIBITORS | ZENECA LIMITED (GB) | 1996-09-25 | — | — | EP | disclosed |
| WO-1995015952-A1 | 4,6-DIANILINO-PYRIMIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS TYROSINE KINASE INHIBITORS | ZENECA LIMITED (GB) | 1995-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253607-A1 | ORGANOSILANES FOR THE TREATMENT OF INFECTIONS | ASNS, ACMSD, ARG1 | TSHR 4175/4885MAPK1 3834/4885MEN1 1482/4885 |
| US-12180239-B2 | Organosilanes for the treatment of infections | ASNS, ACMSD, ARG1 | TSHR 4175/4885MAPK1 3834/4885MEN1 1482/4885 |
| US-20250304604-A1 | ORGANOSILANES FOR THE TREATMENT OF INFECTIONS | ASNS, ACMSD, ARG1 | TSHR 4175/4885MAPK1 3834/4885MEN1 1482/4885 |
| US-20100286101-A1 | PHARMACEUTICAL COMPOSITION INCLUDING A CORTICOSTEROID AND A VITAMIN D ANALOG HAVING IMPROVED STABILITY | CYP24A1, CYP2R1, VDR | TSHR 1880/4885MAPK1 4138/4885MEN1 3298/4885 |
| US-20230295195-A1 | ANTIMICROBIAL ORGANOSILANES | ARG1, ACMSD, AAAS | TSHR 4128/4885MAPK1 3701/4885MEN1 2477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.